Pfizer Inc said on Tuesday it will start a large study to test its COVID-19 vaccine in children below 12 and selected a dosing regime for the trial.
The study will enroll up to 4,500 children at more than 90 clinical sites in the United States, Finland, Poland and Spain, the company said.
Get weekly health news
READ MORE: What we know about the heart reaction reported after COVID-19 vaccines
Pfizer’s vaccine has been authorized for use in children as young as 12 in Europe, the United States and Canada.
- Chinese consulate met Vancouver official in bid to stop event critical of communist rule
- Cargo ship near Strait of Hormuz says it’s attacked as Iran pushes new peace deal
- Carney to take part in European summit on security, trade
- Video of NYC police killing machete-wielding man at Grand Central station released
The company said it has selected a dose of 10 micrograms in children between five and 11 years of age and three micrograms for infants in age-group of six months to five years -old.
Inoculating children and young people is considered a critical step toward reaching “herd immunity” and taming the COVID-19 pandemic.
Comments
Want to discuss? Please read our Commenting Policy first.